SCHEMBL6294124

SCHEMBL6294124

COc1ccccc1C1CC(c2ccccc2O)=NN1c1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESD P10768 1/20 0.52
MAOA P21397 4/20 0.51
MAOB P27338 3/20 0.51
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
ATM Q13315 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
HSP90AA1 P07900 1/20 0.46
PDE5A O76074 1/20 0.45
PDCD1 Q15116 1/20 0.44
CD274 Q9NZQ7 1/20 0.44
AOC1 P19801 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6298325 0.89 ESD (0.60) ESDMAOAMAOBKMT2AMEN1
SCHEMBL6298319 0.83 PDE5A (0.65) ESDMAOAMAOBKMT2AMEN1
SCHEMBL7131258 0.82 MAOA (0.48) ESDMAOAMAOBKMT2AMEN1
SCHEMBL6292699 0.80 ESD (0.75) ESDMAOAMAOBKMT2AMEN1
SCHEMBL6294160 0.80 ESD (0.58) ESDMAOAMAOBKMT2AMEN1
SCHEMBL6294300 0.79 ESD (0.63) ESDMAOAMAOBKMT2AMEN1
SCHEMBL7127148 0.72 ESD (0.49) ESDKMT2AMEN1HSP90AA1
SCHEMBL27997401 0.68 ESD (1.00) ESDMAOAMAOBKMT2AMEN1
SCHEMBL6297386 0.68 MAOB (0.49) MAOAMAOBKMT2AMEN1ATM
SCHEMBL6015104 0.65 PDCD1 (0.46) KMT2AMEN1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050090532-A1 Medicinal uses of dihydropyrazoles THE PROCTER & GAMBLE COMPANY 2005-04-28 US claimed
US-6878729-B2 Medicinal uses of dihydropyrazoles THE PROCTER & GAMBLE COMPANY (US) 2005-04-12 US claimed
US-20030083351-A1 Medicinal uses of dihydropyrazoles THE PROCTER & GAMBLE COMPANY 2003-05-01 US claimed
WO-2002089799-A2 USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 WO claimed
US-20050090532-A1 Medicinal uses of dihydropyrazoles THE PROCTER & GAMBLE COMPANY 2005-04-28 US disclosed
US-6878729-B2 Medicinal uses of dihydropyrazoles THE PROCTER & GAMBLE COMPANY (US) 2005-04-12 US disclosed
WO-2002089799-A2 USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090532-A1 Medicinal uses of dihydropyrazoles EPOR, VEGFA, FLT4 ESD 2222/4885MAOA 816/4885MAOB 437/4885
US-20030083351-A1 Medicinal uses of dihydropyrazoles EPOR, VEGFA, TEK ESD 2918/4885MAOA 1212/4885MAOB 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.